TY - JOUR
T1 - Myeloid-Derived Suppressor Cell Membrane-Coated Magnetic Nanoparticles for Cancer Theranostics by Inducing Macrophage Polarization and Synergizing Immunogenic Cell Death
AU - Yu, Guang Tao
AU - Rao, Lang
AU - Wu, Hao
AU - Yang, Lei Lei
AU - Bu, Lin Lin
AU - Deng, Wei Wei
AU - Wu, Lei
AU - Nan, Xiaolin
AU - Zhang, Wen Feng
AU - Zhao, Xing Zhong
AU - Liu, Wei
AU - Sun, Zhi Jun
N1 - Publisher Copyright:
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2018/9/12
Y1 - 2018/9/12
N2 - A major challenge for traditional cancer therapy, including surgical resection, chemoradiotherapy, and immunotherapy, is how to induce tumor cell death and leverage the host immune system at the same time. Here, a myeloid-derived suppressor cell (MDSC) membrane-coated iron oxide magnetic nanoparticle (MNP@MDSC) to overcome this conundrum for cancer therapy is developed. In this study, MNP@MDSC demonstrates its superior performance in immune evasion, active tumor-targeting, magnetic resonance imaging, and photothermal therapy (PTT)-induced tumor killing. Compared with red blood cell membrane-coated nanoparticles (MNPs@RBC) or naked MNPs, MNP@MDSCs are much more effective in active tumor-targeting, a beneficial property afforded by coating MNP with membranes from naturally occurring MDSC, thus converting the MNP into “smart” agents that like to accumulate in tumors as the source MDSCs. Once targeted to the tumor microenvironment, MNPs@MDSC can act as a PTT agents for enhanced antitumor response by inducing immunogenic cell death, reprogramming the tumor infiltrating macrophages, and reducing the tumor's metabolic activity. These benefits, in combination with the excellent biocompatibility and pharmacological kinetics characteristics, make MNP@MDSC a promising, multimodal agent for cancer theranostics.
AB - A major challenge for traditional cancer therapy, including surgical resection, chemoradiotherapy, and immunotherapy, is how to induce tumor cell death and leverage the host immune system at the same time. Here, a myeloid-derived suppressor cell (MDSC) membrane-coated iron oxide magnetic nanoparticle (MNP@MDSC) to overcome this conundrum for cancer therapy is developed. In this study, MNP@MDSC demonstrates its superior performance in immune evasion, active tumor-targeting, magnetic resonance imaging, and photothermal therapy (PTT)-induced tumor killing. Compared with red blood cell membrane-coated nanoparticles (MNPs@RBC) or naked MNPs, MNP@MDSCs are much more effective in active tumor-targeting, a beneficial property afforded by coating MNP with membranes from naturally occurring MDSC, thus converting the MNP into “smart” agents that like to accumulate in tumors as the source MDSCs. Once targeted to the tumor microenvironment, MNPs@MDSC can act as a PTT agents for enhanced antitumor response by inducing immunogenic cell death, reprogramming the tumor infiltrating macrophages, and reducing the tumor's metabolic activity. These benefits, in combination with the excellent biocompatibility and pharmacological kinetics characteristics, make MNP@MDSC a promising, multimodal agent for cancer theranostics.
KW - immunogenic cell death
KW - macrophage
KW - magnetic resonance imaging
KW - myeloid-derived suppressor cell
KW - photothermal therapy
UR - http://www.scopus.com/inward/record.url?scp=85052997102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052997102&partnerID=8YFLogxK
U2 - 10.1002/adfm.201801389
DO - 10.1002/adfm.201801389
M3 - Article
AN - SCOPUS:85052997102
SN - 1616-301X
VL - 28
JO - Advanced Functional Materials
JF - Advanced Functional Materials
IS - 37
M1 - 1801389
ER -